Courses & Schedule

The False Claims Act in the Health Care Industry
Professor Asha Scielzo with Mr. John T. Boese

Though the False Claims Act is designed to prevent many types of fraud committed by federal contractors, it has particular importance in the health care industry. FCA cases predicated on the submission of health care claims are increasingly common and lucrative. The statute's "qui tam" provisions provide a financial incentive for individuals to bring allegations of fraud on behalf of the Government and be paid a percentage of the recovery. This course will review the elements of the False Claims Act and consider enforcement, defense strategies and qui tam provisions, with specific emphasis on understanding the impact of the FCA on the health care industry.
(Students who took Health Care Fraud and Abuse during the 2015 WCL Health Law & Policy Summer Institute may not take this course.)

Pharmaceuticals and the Law
Mr. Daniel Kracov with Ms. Allison Shuren and Ms. Rosemary Maxwell

As the government determines or influences virtually every aspect of how drugs are developed and delivered to patients, it is important to understand the complex framework governing pharmaceutical innovation and patient access to new therapies. This course will provide an introduction to the range of legal and policy issues relevant to the biopharmaceutical industry, including: (1) the regulation of drug and biologic development, approval, and promotion; (2) laws and regulations governing access to biopharmaceuticals and other types of care under large government healthcare programs; (3) fraud and abuse laws and regulations and "transparency" policy trends, including disclosure of and restrictions on interactions with healthcare providers; (4) "healthcare reform" policy trends, including cost containment, "value-based" payment methods for drugs, expanding coverage for the uninsured, and improving the quality of healthcare; (5) statutory intellectual property protections for biopharmaceuticals, including patent-related processes and various exclusivities; (6) the interplay between biopharmaceutical regulation and product liability; and (7) First Amendment issues arising in the regulation of various pharmaceutical industry activities.

Health Care Business Transactions
Professor Asha Scielzo

This course is designed to introduce students to the myriad of business and legal issues that arise in health care transactions and the regulatory environment surrounding such transactions. This course will cover health care mergers & acquisitions, joint ventures, and physician contracting, with insights into the key legal considerations, such as tax, antitrust, fraud and abuse, among others. The goal of this course is to provide students with practical knowledge and an opportunity to participate in contract review and issue spotting, along with a discussion of negotiating tactics.

Monday (June)
12
Tuesday
13
Wednesday
14
Thursday
15
Friday
16
Saturday
17
9:00 a.m. - 4:30 p.m.9:00 a.m. - 4:30 p.m. 9:00 a.m. - 4:30 p.m.9:00 a.m. - 4:30 p.m. 9:00 a.m. - 4:30 p.m.9:00 a.m. - 4:30 p.m.

The False Claims Act in the Health Care Industry
Professor Asha Scielzo with Mr. John T. Boese

The False Claims Act in the Health Care Industry
Professor Asha Scielzo with Mr. John T. Boese

Pharmaceuticals and the Law
Mr. Daniel Kracov

Pharmaceuticals and the Law
Mr. Daniel Kracov

Health Care Business Transactions
Professor Asha Scielzo
Health Care Business Transactions
Professor Asha Scielzo